Application of Multimodal Imaging Biomarker in the Differential Diagnosis of Ovarian Mass: Integration of Conventional and Molecular Imaging. (February 2022)

• Record Type: Journal Article
• Authors: Bang, Ji-In; Kim, Ji-Young; Choi, Min Chul; Lee, Ho-Young; Jang, Su Jin
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 2(2022)
• Publication Date: 2022-02
• Subjects: 18F-FDG -- positron emission computed tomography -- ovarian neoplasm -- magnetic resonance imaging -- differential diagnosis; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004008
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Purpose: The aim is to investigate the diagnostic performance of multimodal imaging with 18 F-FDG PET/CT, MRI, and contrast-enhanced CT (CECT) in cases with unilateral or bilateral ovarian mass without ancillary findings of malignancy. Methods: Retrospectively, 307 patients who had unilateral or bilateral ovarian masses and underwent preoperative FDG PET/CT and/or MRI/CECT were included. The criterion standard for the ovarian mass was the final pathology. The peak standardized uptake value (SULpeak ) among benign tumors (BTs), borderline ovarian tumors (BoTs), and malignant ovarian tumors (MTs) were compared. The cutoff value of SULpeak to discriminate between BT/BoT and MT was determined from the training (n = 200) and validation (n = 131) cohorts. Diagnostic performances of SULpeak, Ovarian-Adnexal Reporting Data System (O-RADS) MRI score, CECT findings, and combination of multimodal imagings were analyzed. Results: SULpeak of MT was significantly higher than that of BT or BoT ( P < 0.05). There was no significant difference in SULpeak between BT and BoT ( P = 0.147). The cutoff value of SULpeak for discriminating between BT/BoT and MT was 1.76 (sensitivity, 87.0%; specificity, 83.0%). Diagnostic performance for BT/BoT versus MT of O-RADS MRI, CECT, FDG PET/CT plus O-RADS MRI score, and FDG PET/CT plus CECT yielded the respective sensitivities of 100%, 94%, 95%, and 82%, and specificities of 43%, 46%, 88%, and 91%, respectively. Conclusions: Multimodal imaging biomarkers including FDG PET/CT and MR/CECT could provide additional information to differentiate ovarian masses. Abstract : Supplemental digital content is available in the text.